The toxicity of plants containing certain pyrrolizidine alkaloids has long been recognized in grazing animals and humans. Genotoxicity and carcinogenicity data from in vitro and in vivo (animal) studies were published over the last few decades for some of the 1,2-unsaturated pyrrolizidine alkaloids, leading to regulatory action on herbal medicinal products with pyrrolizidine alkaloid-containing plants more than 30 years ago. In recent years, it has become evident that in addition to herbal medicinal products containing pyrrolizidine alkaloid-containing plants, these products may also contain pyrrolizidine alkaloids without actually including pyrrolizidine alkaloid-containing plants. This is explained by contamination by accessory herbs (weeds). The national competent authorities of the European member states and the European Medicines Agency, in this case, the Committee on Herbal Medicinal Products, reacted to these findings by setting limits for all herbal medicinal products. This review article will briefly discuss the data leading to the establishment of thresholds and the regulatory developments and consequences, as well as the current discussions and research in this area.
Bei den Anforderungen an die präklinische Prüfung von pflanzlichen Arzneimitteln gibt es eine Reihe von Vereinfachungen/Erleichterungen. Dies gilt speziell im Bereich der Genotoxizitätsprüfung, entbindet aber nicht davon, die vorgelegten Ergebnisse kritisch zu hinterfragen. Die Besonderheiten pflanzlicher Arzneimittel können fallweise genutzt werden, um den Prüfumfang sinnvoll zu reduzieren; es muss andererseits akzeptiert werden, dass diese Besonderheiten auch eine Reihe von Fragen aufwerfen, auf die dann fallspezifisch eingegangen werden muss. Aufgrund der komplexen Zusammensetzung pflanzlicher Vielstoffgemische sind Lücken zwischen den regulatorischen Forderungen und den angemessenen experimentellen Möglichkeiten unvermeidbar. Es ist die Aufgabe des präklinischen Gutachtens, diese Lücken durch qualifizierte Aufbereitung der vorhandenen Daten zu diskutieren. Tests on genotoxicity for herbal medicinal products. Demands, pragmatic attempts, and discussions With respect to the common medicinal and traditional use of herbal medicinal products, there is a possibility to reduce the set of tests to be performed in the context of preclinical testing. This is especially the case for tests on genotoxicity, although it does not replace a critical discussion of the relevant data. Consideration of the particulars of herbal medicinal products does not only offer the chance to reduce the testing adequately but also provokes some additional questions which should be addressed case by case. There is an inevitable gap between regulatory requirements and sound experimental methodology. It is a major task of the preclinical expert report to bridge this gap by means of a qualified discussion and interpretation of the available data.